Provided by Tiger Trade Technology Pte. Ltd.

Immix Biopharma, Inc.

8.12
+0.790010.78%
Post-market: 8.310.1871+2.30%19:41 EST
Volume:895.23K
Turnover:7.08M
Market Cap:430.00M
PE:-10.44
High:8.25
Open:7.40
Low:7.36
Close:7.33
52wk High:8.25
52wk Low:1.34
Shares:52.96M
Float Shares:41.44M
Volume Ratio:0.81
T/O Rate:2.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7776
EPS(LYR):-0.7641
ROE:-182.55%
ROA:-66.48%
PB:52.03
PE(LYR):-10.63

Loading ...

Immix Biopharma (IMMX) Gets a Buy from Mizuho Securities

TIPRANKS
·
Feb 16

Immix Biopharma Inc : Mizuho Initiates Coverage With Outperform Rating; Price Target $14

THOMSON REUTERS
·
Feb 09

Immix Biopharma Inc. unveils new presentation on relapsed/refractory AL amyloidosis treatment challenges

Reuters
·
Feb 05

BUZZ-Immix climbs on FDA's 'breakthrough' tag for blood disorder therapy

Reuters
·
Jan 28

FDA Grants Breakthrough Therapy Designation to Immix Biopharma's NXC-201 for AL Amyloidosis

Reuters
·
Jan 28

Immix Biopharma Receives U.S. FDA Breakthrough Therapy Designation for Nxc-201

THOMSON REUTERS
·
Jan 28

Immix Biopharma Inc: Final Data Expected This Year Followed by Planned Bla Submission

THOMSON REUTERS
·
Jan 28

Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities

Benzinga_recent_news
·
Jan 12

BRIEF-Immix Biopharma To Offer And Sell Up To $750 Million In Securities - SEC Filing

Reuters
·
Jan 10

Immix Biopharma files $750M mixed securities shelf

TIPRANKS
·
Jan 10

Immix Biopharma Inc - to Offer and Sell up to $750 Mln in Securities - SEC Filing

THOMSON REUTERS
·
Jan 10

Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges

Reuters
·
Jan 10

Immix Biopharma CEO Ilya Rachman Acquires Common Shares

Reuters
·
Dec 11, 2025

Immix Biopharma CFO Gabriel S. Morris Reports Acquisition of Common Shares

Reuters
·
Dec 11, 2025

BRIEF-Immix Biopharma Announces Closing Of Upsized $100 Million Underwritten Offering Of Common Stock And Pre-Funded Warrants

Reuters
·
Dec 10, 2025

Immix Biopharma Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Dec 09, 2025

Immix Biopharma, Inc. : H.c. Wainwright Raises Target Price to $12 From $8

THOMSON REUTERS
·
Dec 09, 2025

Immix Biopharma Inc. unveils presentation on relapsed/refractory AL amyloidosis treatment challenges

Reuters
·
Dec 09, 2025

BRIEF-Immix Biopharma Prices Offering Of 19.1 Million Shares At $5.10 Per Share

Reuters
·
Dec 08, 2025

Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

THOMSON REUTERS
·
Dec 08, 2025